ForPatients

by Roche

Geographic Atrophy

A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Trial Status	Trial Runs In	Trial Identifier
Recruiting	1 Countries	NCT05626114 GR44251

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This study will evaluate the success and safety of subretinal surgical delivery as well as the preliminary activity of OpRegen in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). All endpoints are assessed for the study eye unless otherwise indicated.

Genentech, Inc. Sponsor		Phase 2 Phase		
NCT05626114 GR44251 Trial Identifiers				
Eligibility Criteria:				
Gender All	Age >=50 Years		Healthy Volunteers	